SG11201509920UA - Polymorphic forms of icotinib and uses thereof - Google Patents

Polymorphic forms of icotinib and uses thereof

Info

Publication number
SG11201509920UA
SG11201509920UA SG11201509920UA SG11201509920UA SG11201509920UA SG 11201509920U A SG11201509920U A SG 11201509920UA SG 11201509920U A SG11201509920U A SG 11201509920UA SG 11201509920U A SG11201509920U A SG 11201509920UA SG 11201509920U A SG11201509920U A SG 11201509920UA
Authority
SG
Singapore
Prior art keywords
icotinib
polymorphic forms
polymorphic
forms
Prior art date
Application number
SG11201509920UA
Inventor
Shaojing Hu
Wei Long
Fei Wang
Yinxiang Wang
Lieming Ding
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of SG11201509920UA publication Critical patent/SG11201509920UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
SG11201509920UA 2013-06-09 2014-06-09 Polymorphic forms of icotinib and uses thereof SG11201509920UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013077095 2013-06-09
PCT/CN2014/079491 WO2014198212A1 (en) 2013-06-09 2014-06-09 Polymorphic forms of icotinib and uses thereof

Publications (1)

Publication Number Publication Date
SG11201509920UA true SG11201509920UA (en) 2016-01-28

Family

ID=52021658

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201509920UA SG11201509920UA (en) 2013-06-09 2014-06-09 Polymorphic forms of icotinib and uses thereof

Country Status (13)

Country Link
US (1) US9611272B2 (en)
EP (1) EP3008071B1 (en)
JP (1) JP6216869B2 (en)
KR (1) KR101804449B1 (en)
AU (1) AU2014280711B2 (en)
BR (1) BR112015030751B1 (en)
CA (1) CA2914857C (en)
ES (1) ES2666335T3 (en)
HK (1) HK1207641A1 (en)
RU (1) RU2710013C2 (en)
SG (1) SG11201509920UA (en)
TW (1) TWI529174B (en)
WO (1) WO2014198212A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2638646T3 (en) * 2013-06-09 2017-10-23 Betta Pharmaceuticals Co., Ltd. New polymorphic forms of Icotinib phosphate and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078409B2 (en) * 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US8822482B2 (en) * 2008-07-08 2014-09-02 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof
ES2641953T3 (en) * 2011-10-31 2017-11-14 Beta Pharmaceuticals Co., Ltd. Methods of preparation of Icotinib and Icotinib hydrochloride, and intermediaries thereof

Also Published As

Publication number Publication date
RU2016100028A3 (en) 2018-03-29
BR112015030751A2 (en) 2017-07-25
US20160108055A1 (en) 2016-04-21
CA2914857C (en) 2017-08-22
ES2666335T3 (en) 2018-05-04
RU2710013C2 (en) 2019-12-24
JP6216869B2 (en) 2017-10-18
AU2014280711B2 (en) 2017-04-13
CA2914857A1 (en) 2014-12-18
KR20160018735A (en) 2016-02-17
BR112015030751B1 (en) 2022-08-30
TWI529174B (en) 2016-04-11
HK1207641A1 (en) 2016-02-05
WO2014198212A1 (en) 2014-12-18
KR101804449B1 (en) 2017-12-04
AU2014280711A1 (en) 2016-01-21
TW201506029A (en) 2015-02-16
RU2016100028A (en) 2017-07-18
EP3008071A4 (en) 2016-10-19
US9611272B2 (en) 2017-04-04
JP2016526046A (en) 2016-09-01
EP3008071B1 (en) 2018-02-28
EP3008071A1 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
IL274355B (en) Aza-pyridone compounds and uses thereof
HK1216380A1 (en) Attachment apparatuses and associated methods of use and manufacture
GB2535360B (en) Methods of preparing polyhemiaminals and polyhexahydrotriazines
EP2964235A4 (en) Antimicrobial-antibiofilm compositions and methods of use thereof
HRP20181710T1 (en) Use of benzimidazole-proline derivatives
GB201323008D0 (en) Compounds and uses thereof
HK1224307A1 (en) Protoxin-ii variants and methods of use -ii
GB201312318D0 (en) Novel methods and compounds
HK1218388A1 (en) Onapristone polymorphic forms and methods of use
SG11201507389RA (en) Integration of hydro-dechlorination and hydro-regeneration
GB201307233D0 (en) Compounds and uses thereof
HK1203179A1 (en) Structural assembly and method of assembly thereof
IL241290A0 (en) Sovaprevir polymorphs and methods of manufacture thereof
HK1223307A1 (en) Novel compounds and uses thereof
HK1207589A1 (en) Polymorphic forms of icotinib phosphate and uses thereof
HK1207641A1 (en) Polymorphic forms of icotinib and uses thereof
GB201308639D0 (en) Biomarkers and uses of thereof
EP2968557A4 (en) Enhancement of vaccines
ZA201508950B (en) New polymorphic forms of icotinib phosphate and uses thereof
ZA201508951B (en) Polymorph forms of icotinib maleate and uses thereof
HK1207644A1 (en) Polymorph forms of icotinib maleate and uses thereof
HK1198422A1 (en) Novel uses of colossolactones
SG11201509750VA (en) Polymorph forms of icotinib maleate and uses thereof
TWM475821U (en) Structure of mosquito-catch
TWM475524U (en) Structure of rivet-pulling